Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.45 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595227 | 0.91 | KMT2A (0.41) | KDRBRAFAURKALCKIGF1R | |
| SCHEMBL20595235 | 0.91 | KDR (0.44) | KDRBRAFAURKALCKIGF1R | |
| SCHEMBL22797751 | 0.90 | MEN1 (0.48) | KDRBRAFAURKALCKIGF1R | |
| SCHEMBL22798330 | 0.85 | SCN9A (0.47) | SCN9ASCN10A | |
| SCHEMBL22797805 | 0.84 | GSK3B (0.52) | KDRBRAFABL1MAPTMET | |
| SCHEMBL2715187 | 0.81 | GSK3B (0.44) | KDRBRAFSYKSSTR4NPC1 | |
| SCHEMBL22797756 | 0.81 | SCN9A (0.51) | KDRBRAFABL1SSTR4SMN1; SMN2 | |
| SCHEMBL22797760 | 0.81 | SCN9A (0.54) | KDRBRAFAURKALCKIGF1R | |
| SCHEMBL22798307 | 0.80 | GSK3B (0.42) | KDRBRAFSMN1; SMN2MEN1LMNA | |
| SCHEMBL20595168 | 0.79 | KDR (0.46) | KDRBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | claimed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | claimed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | claimed |
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | KDR 4122/4885BRAF 1661/4885AURKA 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.